Establishment Labs (ESTA) Stock Price, News & Analysis

Company Overview

Establishment Labs (NASDAQ: ESTA) is a medical device company focused on the design, development and manufacture of advanced aesthetic surgical products for the global breast implant market. Founded in 2004 and headquartered in Alajuela, Costa Rica, the company develops proprietary technologies that address both cosmetic and reconstructive needs. Its flagship product line, Motiva Implants, offers a range of smooth-surface and textured implants engineered for natural feel and tissue integration while incorporating safety and performance innovations.

The company’s Motiva Ergonomix and Round SilkSurface implants are manufactured under ISO 13485 quality standards and leverage the proprietary ProgressiveGel Ultima filling material. A key differentiator is the Q Inside Safety Technology, an embedded radiofrequency identification (RFID) microchip that enables non-invasive product tracing and patient-specific information access. Establishment Labs also provides comprehensive surgeon training programs, clinical support services and digital tools to enhance procedural outcomes and post-operative follow-up.

Establishment Labs serves a broad network of plastic surgeons and health care providers across North America, Europe, Latin America and select markets in the Asia-Pacific region. The company has secured multiple regulatory approvals, including US FDA clearance and CE Mark certification, supporting its growth in both established and emerging markets. Manufacturing operations in Costa Rica and strategic partnerships for distribution help ensure supply chain resilience and facilitate expansion into new territories.

Under the leadership of founder and CEO Raúl A. Garcia, Establishment Labs has positioned itself at the forefront of implant innovation through ongoing investment in research and development, collaboration with key opinion leaders and commitment to patient safety. The company’s leadership team combines medical device expertise, regulatory experience and commercial acumen to drive global adoption of its products and reinforce its reputation for quality and innovation in the aesthetic surgery sector.

Key Stats

• Today's Range: $45.00 to $45.82
• 50-Day Range: $33.08 to $46.11
• 52-Week Range: $26.56 to $52.41
• Volume: 10,117 shs
• Average Volume: 554,148 shs
• Market Capitalization: $1.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.80
• Consensus Rating: Moderate Buy

Establishment Labs Stock Analysis - MarketRank™

Establishment Labs scored higher than 33% of companies evaluated by MarketBeat, and ranked 774th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Establishment Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Establishment Labs has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Establishment Labs are expected to grow in the coming year, from ($2.41) to ($1.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Establishment Labs is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Establishment Labs is -14.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Establishment Labs has a P/B Ratio of 24.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.45% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Establishment Labs has recently increased by 3.42%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Establishment Labs does not currently pay a dividend.

Dividend Growth

Establishment Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.45% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Establishment Labs has recently increased by 3.42%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.99

News Sentiment

Establishment Labs has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Establishment Labs this week, compared to 4 articles on an average week.

MarketBeat Follows

Only 1 people have added Establishment Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Establishment Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.09% of the stock of Establishment Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.91% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ESTA Stock Analysis - Frequently Asked Questions

How have ESTA shares performed this year?

Establishment Labs' stock was trading at $46.07 at the beginning of 2025. Since then, ESTA shares have decreased by 0.2% and is now trading at $45.97.

How were Establishment Labs' earnings last quarter?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) issued its earnings results on Wednesday, May, 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs's quarterly revenue was up 11.3% on a year-over-year basis.
Read the conference call transcript.

When did Establishment Labs IPO?

Establishment Labs (ESTA) raised $50 million in an IPO on Thursday, July 19th 2018. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and BTIG was co-manager.

Who are Establishment Labs' major shareholders?

Establishment Labs' top institutional investors include Guided Capital Wealth Management LLC (0.17%). Insiders that own company stock include Nicholas Sheridan Lewin, Quiros Juan Jose Chacon, Raj Denhoy, Raj Denhoy and Leslie Gillin.
View institutional ownership trends.

How do I buy shares of Establishment Labs?

Shares of ESTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Establishment Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Establishment Labs investors own include PayPal (PYPL), NVIDIA (NVDA), Walt Disney (DIS), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ESTA
• CIK: 1688757
• Web: www.establishmentlabs.com
• Phone: (062) 434-2400
• Fax: N/A
• Employees: 1,018
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Establishment Labs: $51.80
• High Price Target: $62.00
• Low Price Target: $47.00
• Potential Upside/Downside: +12.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.60 million
• Net Margins: -52.34%
• Pretax Margin: -52.08%
• Return on Equity: -196.25%
• Return on Assets: -26.64%

Debt

• Debt-to-Equity Ratio: 5.72
• Current Ratio: 3.36
• Quick Ratio: 2.05

Sales & Book Value

• Annual Sales: $166.02 million
• Price / Sales: 8.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.90 per share
• Price / Book: 24.19

Miscellaneous

• Outstanding Shares: 28,920,000
• Free Float: 25,710,000
• Market Cap: $1.33 billion
• Optionable: Optionable
• Beta: 0.80